Sen­ti Bio cuts 37% of staff; Evotec pock­ets $25M mile­stone from BMS; No­var­tis buys San­Reno

Plus news about Ory­zon Ge­nomics, Cu­mu­lus On­col­o­gy, Cure­Vac, Ori­on, Glykos Fin­land, Ra­di­ance Bio­phar­ma, Bio­cy­to­gen, Mark­er Ther­a­peu­tics and Hill­e­Vax:

Sen­ti Bio will lay off 37% of its staff: The cell and gene ther­a­py de­vel­op­er will al­so scale back some R&D work to fo­cus on its clin­i­cal pro­grams. CEO Tim­o­thy Lu says these are “dif­fi­cult but nec­es­sary steps” as it gath­ers proof-of-con­cept da­ta for its gene cir­cuit tech­nol­o­gy. The biotech ex­pects to dose the first acute myeloid leukemia pa­tient with its log­ic-gat­ed cell ther­a­py SEN­TI-202 in the sec­ond quar­ter of 2024. It will al­so con­tin­ue to sup­port a dif­fer­ent can­di­date, tar­get­ed at glyp­i­can 3-ex­press­ing he­pa­to­cel­lu­lar car­ci­no­ma, through a part­ner­ship in Chi­na. — Am­ber Tong

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER